Unknown

Dataset Information

0

High-throughput binding affinity calculations at extreme scales.


ABSTRACT: BACKGROUND:Resistance to chemotherapy and molecularly targeted therapies is a major factor in limiting the effectiveness of cancer treatment. In many cases, resistance can be linked to genetic changes in target proteins, either pre-existing or evolutionarily selected during treatment. Key to overcoming this challenge is an understanding of the molecular determinants of drug binding. Using multi-stage pipelines of molecular simulations we can gain insights into the binding free energy and the residence time of a ligand, which can inform both stratified and personal treatment regimes and drug development. To support the scalable, adaptive and automated calculation of the binding free energy on high-performance computing resources, we introduce the High-throughput Binding Affinity Calculator (HTBAC). HTBAC uses a building block approach in order to attain both workflow flexibility and performance. RESULTS:We demonstrate close to perfect weak scaling to hundreds of concurrent multi-stage binding affinity calculation pipelines. This permits a rapid time-to-solution that is essentially invariant of the calculation protocol, size of candidate ligands and number of ensemble simulations. CONCLUSIONS:As such, HTBAC advances the state of the art of binding affinity calculations and protocols. HTBAC provides the platform to enable scientists to study a wide range of cancer drugs and candidate ligands in order to support personalized clinical decision making based on genome sequencing and drug discovery.

SUBMITTER: Dakka J 

PROVIDER: S-EPMC6302294 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

High-throughput binding affinity calculations at extreme scales.

Dakka Jumana J   Turilli Matteo M   Wright David W DW   Zasada Stefan J SJ   Balasubramanian Vivek V   Wan Shunzhou S   Coveney Peter V PV   Jha Shantenu S  

BMC bioinformatics 20181221 Suppl 18


<h4>Background</h4>Resistance to chemotherapy and molecularly targeted therapies is a major factor in limiting the effectiveness of cancer treatment. In many cases, resistance can be linked to genetic changes in target proteins, either pre-existing or evolutionarily selected during treatment. Key to overcoming this challenge is an understanding of the molecular determinants of drug binding. Using multi-stage pipelines of molecular simulations we can gain insights into the binding free energy and  ...[more]

Similar Datasets

| S-EPMC6787036 | biostudies-literature
| S-EPMC10121719 | biostudies-literature
| S-EPMC6538633 | biostudies-literature
2023-02-10 | GSE207640 | GEO
| S-EPMC7577374 | biostudies-literature
| S-EPMC4394037 | biostudies-literature
| S-EPMC10286572 | biostudies-literature
| S-EPMC6041321 | biostudies-literature
| S-EPMC7328786 | biostudies-literature
| S-EPMC2975913 | biostudies-literature